Association of graft survival with tacrolimus metabolism in pediatric and young adult kidney transplant recipients: an international Collaborative Transplant Study analysis.
Abstract
INTRODUCTION Evidence on the association between tacrolimus concentration-to-dose ratio (CDR), a surrogate marker of tacrolimus metabolism, and graft outcome in pediatric and young adult kidney transplant recipients is limited.
Methods
We retrospectively analyzed 3768 pediatric (1-17 years old) and young adult (18-24 years old) kidney transplant recipients from the Collaborative Transplant Study database. CDR was assessed at one year post-transplant and normalized to body weight to account for pediatric heterogeneity and improve comparability with adult values. Pediatric recipients were stratified into children (1-11 years) and adolescents (12-17 years). We examined associations between CDR and death-censored graft loss during post-transplant years 2-5.
Results
Adolescents and young adults had a significantly higher risk of graft loss than children (P < 0.001). A one-year CDR below 0.58 was independently associated with an increased risk of graft failure in adolescents (adjusted hazard ratio [aHR] 1.74, P = 0.004) and young adults (aHR 1.98, P < 0.001), but not in children (P = 0.98). CDR was below 0.58 in 25.2% of adolescents and 13.8% of young adults. Among young adults, its association with graft failure was stronger in patients with higher immune reactivity (positive PRA at baseline, P < 0.001).
Conclusions
In the largest cohort to date of pediatric and young adult kidney transplant recipients receiving tacrolimus-based immunosuppression, low CDR identified adolescents and young adults as a high-risk subgroup for graft loss, whereas graft survival in children was largely independent of CDR. These findings support age-specific risk stratification and individualized immunosuppression according to developmental stage.